1p19q codeletion
Updates to Article Attributes
1p19q codeletion stands for the combined loss of the short arm chromosome 1 (i.e. 1p) and the long arm of chromosome 19 (19q) and is recognised as a genetic marker predictive of therapeutic response to both chemotherapy and combined chemoradiotherapy and overall longer survival in patients with diffuse gliomas, especially those with oligodendroglial components 1-2, 4.
Historically, the 1p19q codeletion was present in up to 70-85% of oligodendrogliomas and 50% of oligoastrocytomas 1,4. The recent (2016) revision to the WHO classification of CNS tumours has highlighted the importance of 1p19q codeletion by making it essential for the diagnosis of oligodendroglioma (along with the IDH mutation).
In other words:
- IDH positive + 1p19q codeletion = oligodendroglioma = better prognosis
- IDH positive + no 1p19q codeletion = diffuse astrocytoma
When the IDH is negative, it corresponds to thea ‘wild type-type’ and the tumour behaves far more aggressively, with a poor prognosis, similar to that of primary glioblastoma multiforme (GBM) 3. This is discussed further in the article on IDH.
-</ul><p>When the IDH is negative, it corresponds to the ‘wild type’ and the tumour behaves far more aggressively, with a poor prognosis, similar to that of primary <a href="/articles/glioblastoma">glioblastoma</a> (GBM) <sup>3</sup>. This is discussed further in the article on <a href="/articles/isocitrate-dehydrogenase-idh">IDH</a>. </p>- +</ul><p>When the IDH is negative, it corresponds to a ‘wild-type’ and the tumour behaves far more aggressively, with a poor prognosis, similar to that of primary <a href="/articles/glioblastoma">glioblastoma multiforme</a> <sup>3</sup>. This is discussed further in the article on <a href="/articles/isocitrate-dehydrogenase">IDH</a>. </p>
Unable to process the form. Check for errors and try again.